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Abstract 1 
Horses are routinely travelled for access to safe off-road riding, veterinary care, 2 
breeding, sale or moving to a new home environment. However, transport is a known 3 
stressor in horses. For this reason, problem behaviour when loading is a commonly 4 
reported issue which presents risks to handlers and horse welfare. Existing literature 5 
and manufacturers recommendations suggests that alpha-casozepine may be 6 
effective in improving the behaviour and welfare of horses during loading onto a 7 
vehicle for transport. The current paper aims to assess the behavioural and 8 
physiological effects of a commercially available alpha-casozepine feed supplement 9 
(Zylkéne Equine) in horses during loading and confinement on a transport lorry. 10 
Subjects (n = 10) were loaded once with the supplement and once without, in a 11 
balanced random order with each subject acted as their own control. The handler 12 
was blind to treatment. Time to load onto the lorry, and movement of feet, licking and 13 
chewing, and vocalising within the lorry, were recorded as behavioural indicators of 14 
compliance and coping. Heart rate, heart rate variability, salivary cortisol, and 15 
infrared thermography of both core temperature and the discrepancy between eyes, 16 
were measured as indicators of arousal. There were no significant differences in 17 
physiology between Treatment and Control (P > 0.05). Treatment resulted in a 18 
significantly shorter Loading Time than control (P = 0.04), however, the actual 19 
difference in median time was only 0.45 seconds. No other behavioural indicator 20 
differed between Treatment and Control (P > 0.05). Power analysis revealed the 21 
sample was sufficient to detect a significant effect. Where modest effects were 22 
observed for a small number of variables, Treatment effect contradicted predictions. 23 
Taken together, this indicates that alpha-casozepine does not affect a horse’s ability 24 
to cope with loading and confinement in a horse lorry. Further work is required to 25 
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ascertain whether the maximum dosage – twice that used here – might affect coping 26 
and behaviour in horses. 27 
 28 
Keywords: alpha-casozepine; horse loading; infrared thermography; salivary 29 
cortisol; heart rate variability; stress 30 
 31 
Introduction 32 
Horses are routinely travelled for access to safe off-road riding, veterinary care, 33 
breeding, sale or moving to a new home environment. However, transport is a known 34 
stressor in horses (Schmidt et al., 2010) due to features such as confinement, novel 35 
noises, unstable flooring, the presence of unfamiliar conspecifics and sudden 36 
changes in light. For this reason, problem behaviour when loading is a commonly 37 
reported issue, which presents risks to handlers and horse welfare. During loading, 38 
the handler motivates an approximately 500kg animal with a highly evolved flight 39 
response into a confined space, which neither the horse nor handler can easily 40 
escape if an accident occurs. Sedation may be offered to improve behaviour but this 41 
may reduce the motor-control of the animal, increasing the risk of loss of balance 42 
during transport and subsequent injury. Further, sedatives are commonly banned in 43 
horses being transported for competition (FEI, 2018) and sedatives that mainly affect 44 
motor-control may make the horse more manageable and cause them to appear 45 
calmer, without addressing the underlying anxiety trigger by the environment.  46 
Ideally, correctly applied behaviour modification techniques aimed at habituating the 47 
horse and training them to respond to lead-rope pressure should be implemented, 48 
rather than the use of force (McGreevy and McLean, 2009). Such training aims to 49 
improve the horse’s ability to tolerate a stressor, however, this process may still incur 50 
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risk to even experienced trainers. Additionally, it is possible that an animal may need 51 
to be transported at short notice, without the benefit of such training. Therefore, any 52 
practical solutions that may improve the efficacy of training, or limit the welfare 53 
impact of unavoidably stressful events, are warranted. 54 
Dietary supplementation with alpha-casozepine is thought to have anxiolytic 55 
properties. Alpha-casozepine originates from S1 casein, a protein in cow’s milk and 56 
fits into a segment of GABA-B receptors which are responsible for anxiolytic activity 57 
(Landsberg et al., 2017). Whilst research into this supplement is limited, McDonnell 58 
et al., (2014) found a significant improvement in horses’ compliance and comfort 59 
during twelve routine healthcare and treatment procedures when supplemented with 60 
Zylkène Equine, a commercially available alpha-casozepine. This supported 61 
previous findings (McDonnell et al., 2013) which showed that semi-feral ponies 62 
treated with Zylkène whilst undergoing the process of initial training were more calm, 63 
compliant and progressed better than those not having Zylkène in their feed. This 64 
anxiolytic effect is also noted in rats  (Miclo et al., 2001) and cats (Beata et al., 65 
2007). Zylkéne Equine is suggested by the manufacturers for use in loading and 66 
transporting horses (Vetoquinol, 2018). Moreover, it is safe for use and not currently 67 
listed as banned for competition use (FEI, 2018). However, no studies to date have 68 
measured the physiological impact of such supplementation and compliance is not 69 
necessarily an appropriate indicator of coping in horses (Squibb et al., 2018), though 70 
it is highly desirable for handlers. 71 
Physiological indicators of arousal can be measured non-invasively in a number of 72 
ways. Heart Rate Variability (HRV) is advantageous because it can be used to 73 
investigate the functioning of the autonomic nervous system, as variability decreases 74 
with an increase in stress (von Borell et al., 2007). Infrared thermography (IRT) on 75 
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ocular (eye) surface temperature has also been used in horses to monitor stress 76 
responses (Ijichi et al., 2018; Valera et al., 2012). It has been validated against 77 
cortisol (Valera et al., 2012) and can detect fear during novel object tests (Dai et al., 78 
2015). Additionally, a discrepancy in temperature between the left and right eye may 79 
indicate hemispheric dominance indicative of affective state (Lush and Ijichi, 2018), 80 
though this requires further validation. Cortisol is released as a response to stressful 81 
events and can be measured from saliva samples (Yarnell et al., 2013). Studies 82 
based on blood plasma cortisol changes have repeatedly shown that transport is 83 
stressful for horses, however, blood sampling causes stress in itself (e.g. Fazio et al., 84 
2008). As salivary cortisol is validated against blood samples (Peeters et al., 2011), 85 
salivary cortisol sampling is the best candidate for non-invasively sampling rapid 86 
changes in cortisol. 87 
The current experiment aims to assess the effects of a commercially available feed 88 
supplement, Zylkéne Equine, on behaviour and physiology in horses during loading 89 
and confinement on a transport lorry. To this end, subjects were loaded once with 90 
the supplement and once without, in random treatment and subject order. Time to 91 
load onto the lorry, movement of feet, licking and chewing, and vocalising within the 92 
lorry were recorded as behavioural indicators of compliance and coping. Heart rate, 93 
heart rate variability, changes in salivary cortisol and infrared thermography of both 94 
core temperature and the temperature discrepancy between eyes, were measured 95 
as indicators of arousal.  It was hypothesised that horses would load more quickly 96 
but move, vocalise, lick and chew less within the lorry in the treatment, compared to 97 
the control tests. It was also hypothesised that horses would have lower heart rate, 98 
higher heart rate variability, lower core temperature, more negative discrepancy 99 
scores and reduced cortisol changes in the treatment, compared to the control tests. 100 
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 101 
Materials and methods 102 
Subjects 103 
10 healthy horses (6 geldings and 4 mares) of mixed breeds and ages were tested 104 
between 26th March and 12th April 2018. Ages ranged from 8-25 years of age (mean 105 
= 12.6; IQR = 9.25-14.5). Horses were stabled at two private livery yards in 106 
Gloucestershire and were tested in their home environment to reduce the effect of 107 
environmental novelty. Subjects were travelled at least once a month as part of their 108 
normal management routine and had no known phobia to travelling. This restriction 109 
was imposed by  Hartpury Unversity’s ethics committee to ensure high animal 110 
welfare standards were met.  Horses were managed at the discretion of their owners 111 
which meant that workload, turnout and feeding varied according to age and current 112 
use, as well as owner preferences.  113 
 114 
Experimental Design  115 
This was a within-individual experimental design with each subject acting as its own 116 
control. Each subject was loaded once with Zylkéne Equine and once without. The 117 
order of the treatments were randomly allocated. To counterbalance the study there 118 
were equal numbers of supplemented and control horses in each trial. This limited 119 
the possibility of a false positive due to habituation through repeated exposure 120 
(Hawson et al., 2010). Subject order within the group was pseudo-randomised to 121 
account for owner availability. The handler was blind to treatment to prevent any 122 
sub-conscious bias affecting handling and therefore subject responses. Tests were 123 
repeated 2 weeks apart at the same time of day ± 30 minutes. With the exception of 124 
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the test itself, subjects were managed as per their normal daily routine reducing the 125 
impact of differing management of each testing day. A wash-out period has not been 126 
established for this supplement by the manufacturer and so two weeks was used as 127 
an estimated generous wash-out period for subjects receiving Zylkéne in the first 128 
trial. This assumption was tested during data analysis (see 2.9 Statistical Analysis). 129 
 130 
Feeding Protocol 131 
Zylkène Equine was fed once daily for four days prior to testing, as per minimum 132 
dosage in the manufacturer’s instructions (Vetoquinol, 2018). Horses weighing up to 133 
500kg were fed 1000mg daily, while horses over 500kg were fed 2000mg of Zylkène 134 
Equine. Mean subject weight was 492.9kg (±70.34). The researcher met with the 135 
owners of the horses a week before the test was due to take place to provide the 136 
correct amount of Zylkène Equine supplement and ensure that the owner was clear 137 
about how the supplement must be fed. The supplement needed to be fed to the 138 
horses in their morning feeds to ensure that they received their final dose on the 139 
morning that the test took place. Prior to testing on treatment trials, the same 140 
researcher (S.G.) confirmed that the subject had been fed the supplement. Aside 141 
from the addition of the supplement for one trial, feeding was kept as per the 142 
subject’s normal routine.  143 
 144 
 145 
Handling and Loading 146 
The current study used the same Equi-trek rear-facing 3.5t lorry for all tests. The 147 
internal divider was removed to allow the handler to move safely in the lorry with the 148 
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subject and to provide the subjects with more room to express behaviour (Figure 1).  149 
Subjects wore protective equipment such as rugs, travel boots or poll-guards at the 150 
discretion of their owner.  All subjects were handled by the same individual (C.I.) who 151 
is experienced in loading horses and experimental handling and was blind to 152 
treatment. Horses were led to a marker 3.5m from the ramp of the lorry and halted. 153 
Horses were handled using appropriate pressure and release (McGreevy and 154 
McLean, 2009). Forward pressure on the leadrope was used to indicate the horse 155 
should step forward. This was immediately released when the horse complied. If the 156 
horse did not respond to leadrope pressure, they were rhythmically tapped on the 157 
rib-cage first with increasing speed and then increasing intensity if required, until 158 
they took a forward step. Soft vocal cues were also used to indicate correct 159 
responses and tactile positive reinforcement, including wither scratching 160 
(Thorbergson et al., 2016). This was used on loaded horses to encourage them to 161 
stand while the ramps were closed. Once inside the closed lorry, subjects were 162 
cross-tied in the center of the lorry with elasticated safety lines (Figure 1). The 163 
handler then took the post-loading IRT images before stepping through the internal 164 
door and sitting out of the subject’s vision on a stool placed in the equipment 165 
compartment.  Each horse remained within the lorry for 5 minutes, the doors were 166 
then re-opened and the subject unloaded.  167 
 168 
 169 
Infrared Thermography 170 
Using a FLIR E4 thermal imaging camera (FLIR Systems, USA.), the researcher 171 
took an image of both of the subject’s eyes. The camera was held at approximately a 172 
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ninety-degree angle and 1m distance from the eye as accurately as possible within 173 
the confines of the space available. IRT readings were taken in the stable before 174 
testing (S.G.), once loaded onto the lorry when the ramp had been closed and before 175 
the ramp was opened and the horse was unloaded from the lorry (C.I.). The 176 
temperature was analysed for each horse retrospectively using FLIR tools (ver. 177 
5.9.16284.1001). The maximum temperature within the palpebral fissure from the 178 
lateral commissure to the lacrimal caruncle (Yarnell et al., 2013) was used and the 179 
discrepancy between the temperatures for each eye was calculated by subtracting 180 
the temperature of the left eye from the right eye (Lush and Ijichi, 2018). C.I. and 181 
S.G. analysed the images independently and, on the rare instance where they 182 
varied, the highest recorded temperature for each image was used for analysis. The 183 
average of both eyes is referred to as Core Temperature. The difference in 184 
temperature between the eyes is referred to as Temperature Discrepancy. 185 
 186 
HRV Readings 187 
A Polar Equine V800 heart rate monitor (Polar Electro Oy, Kempele, Finland) was 188 
paired to an elasticated adjustable surcingle. This was fitted to each horse after IRT 189 
images were taken but prior to leaving the stable, by wetting the girth area and then 190 
ensuring close contact to ensure conductivity (S.G.). The paired watch was looped 191 
onto the surcingle to ensure that it remained within connectivity boundaries at all 192 
times. Subjects had a minimum of 5 minutes to habituate to the surcingle which was 193 
deemed to be sufficient as all subjects had previously worn girths and/or lunging 194 
rollers. Recordings began at a marker 3.5m meters from the ramp of the lorry and 195 
recorded continuously during loading, confinement and unloading. Recording was 196 
stopped when the horse returned to the marker after unloading.  197 
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Heart rate analysis was carried out by C.I. using Kubios HRV software (ver. 3.0.2 198 
Biomedical Signal Analysis and Medical Imaging Group, Department of Applied 199 
Physics, University of Eastern Finland, Kuopio, Finland.). Kubios settings were 200 
adjusted in line with previous equine studies (Ille et al., 2014; Squibb et al., 2018). 201 
Specifically, artefact correction was set to custom level 0.3, thus removing RR levels 202 
varying by more than 30% from the previous interval. Therefore, where a single RR 203 
interval was more than 30% different from the preceding interval, it was deemed to 204 
be an incorrect reading.  Trend components were adjusted using the concept of 205 
smoothness priors set at 500ms, to avoid the effect of outlying intervals. The STD 206 
RR value, being the standard deviation of RR intervals, was used as the HRV figure 207 
to reflect both short-term and long-term variation with the series of RR intervals. The 208 
root mean square of successive RR intervals (RMSSD value) was recorded as an 209 
indicator of vagal tone (Schmidt et al., 2010). 210 
 211 
Cortisol Samples 212 
Cortisol samples were taken using an Equisal saliva collection kit. The swab was 213 
removed from its packaging and inserted into the side of the horse’s mouth through 214 
the interdental space, between the front and back teeth and above the tongue. The 215 
swab was moved gently around the top of the tongue until enough saliva was 216 
collected. This was judged using the colour change indicator, which turned from 217 
white to pink when sufficiently saturated. Once the sample collection was complete 218 
the swab was placed into a tube and chilled until it could be frozen, awaiting 219 
analysis.   220 
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Two saliva samples were taken, per horse, for each condition. The first sample was 221 
taken in the stable to determine a baseline level of cortisol for each horse by the 222 
same experimenter (S.G.). This was done after IRT readings – to ensure that the 223 
swabbing did not elevate core temperature - but before the heart rate monitor was 224 
fitted – which might affect cortisol in sensitive horses. The second saliva cortisol 225 
sample was taken after 5 minutes within the lorry, after the final IRT images were 226 
taken and before the subject was unloaded. The researcher (C.I) re-entered the 227 
horse compartment through the internal door and took the second sample in the 228 
same method described above. Pre-test cortisol values were subtracted from post-229 
test values to indicate the change in cortisol as a result of loading and confinement 230 
(Table 1). This was to account for any variation in cortisol that was not the result of 231 
testing, such as slight diurnal differences or uncontrollable extraneous sources of 232 
stress. Baseline cortisol, post-test cortisol and changes in cortisol were included in 233 
further analysis. 234 
  235 
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Table 1. Baseline, post-test and change in salivary cortisol levels (μg/dL) for each 236 
subject in treatment and control trials. 237 
 
Treatment Control 
Subject Baseline Post-test Change Baseline Post-test Change 
1 0.3 0.4 0.1 0.19 0.26 0.07 
2 0.14 0.09 -0.05 0.19 0.17 -0.02 
3 0.08 0.101 0.021 0.15 0.13 -0.02 
4 0.24 0.13 -0.11 0.12 0.11 -0.01 
5 0.11 0.16 0.05 0.16 0.07 -0.09 
6 0.05 0.07 0.02 0.12 0.09 -0.03 
7 0.05 0.06 0.01 0.2 0.22 0.02 
8 0.06 0.04 -0.02 0.08 0.04 -0.04 
9 na na na na na na 
10 0.02 0.04 0.02 0.06 0.04 -0.02 
 238 
Samples were analysed by S.G., K.S., A.C. and I.B. Saliva samples were kept within 239 
an ice cooler until transported to the laboratory where they were stored at -20 240 
degrees until analysed. Samples were frozen on the day of sampling within 241 
approximately 4 hours of the saliva collection. To defrost swabs, all samples were 242 
stored at 4 ⁰C Samples were spun down using a centrifuge for approximately 5 243 
minutes at full speed to extract the liquid. 244 
When analysing, all reagents and the microtitre plate were brought to room 245 
temperature before starting the protocol. A 1X wash buffer, enough for the current 246 
day’s requirement, was prepared.. Plate layout was determined with standards, 247 
controls and saliva samples assayed in duplicate. The protocol followed Salimetrics 248 
Assay (Salivary Cortisol ELISA kit) and was as follows: 249 
24 mL of Assay Diluent was pipetted into the disposable tube. 25 μL of standards, 250 
controls, and saliva samples were pipetted into the appropriate wells. 25 μL of Assay 251 
Diluent was pipetted into 2 wells to serve as the zero. 25 μL of Assay Diluent was 252 
pipetted into each non-specific binding well. The Enzyme Conjugate was diluted 253 
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1:1600 by adding 15 μL of the conjugate to the 24 mL tube of Assay Diluent 254 
prepared earlier. The conjugate tube was centrifuged for approximately 5 minutes to 255 
bring the liquid down to the tube bottom. The diluted conjugate solution was mixed 256 
and 200 μL was added to each well. The plate was mixed on a plate rotator for 5 257 
minutes at 500 rpm and incubated at room temperature for a total of 1 hour. The 258 
plate was washed 4 times with the 1X wash buffer. After each wash, the plate was 259 
thoroughly blotted on paper towel before it was turned upright. The plate was mixed 260 
again on a plate rotator for 5 minutes at 500 rpm and incubated in the dark (covered) 261 
at room temperature for an additional 25 minutes. 50 μL of Stop Solution was added 262 
to each well. The plate was mixed on a plate rotator for 3 minutes at 500 rpm. This 263 
was continued until all wells showed a yellow colour. The plate was read in a plate 264 
reader at 450 nm within 10 minutes of adding the Stop Solution. 265 
 266 
Behavioural Observations 267 
Researchers recording behaviour were blind to treatment. The time taken to load 268 
was measured by the same researcher (K.S.) using a stopwatch. Time was started 269 
when the handler stepped past the marker 3.5m from the ramp and ended when the 270 
final hind foot of the subject entered the lorry. Once inside the lorry, horse behaviour 271 
was recorded by a camera mounted on a tripod within the equipment compartment 272 
(C.I.). This recorded through the interior door between the equipment and horse 273 
compartments, which was secured in the open position (Figure 1). The recording 274 
began after the second IRT reading was taken and captured the 5 minute 275 
confinement period that followed.  276 
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Behaviour was recorded by the same researcher (C.I.) as individual instances for 277 
each variable. The number of times the subject moved their feet was recorded as an 278 
indication of frustration causing displaced locomotive behaviour and a failure to 279 
remain immobile (McGreevy and McLean, 2010). This included any instance where 280 
the foot was raised off the ground and included kicking, pawing and steps.  The 281 
number of times the horse expressed licking and chewing behaviour was recorded. 282 
This included sideways movement of the jaw, accompanied by audible grinding, with 283 
or without the protrusion of the tongue. Although the ethological significance of 284 
licking and chewing is not yet fully understood, it is observed during potentially 285 
stressful circumstances (Krueger, 2007). Therefore, it was measured as a 286 
supplementary behavioural indicator. The number of vocalisations was recorded and 287 
characterised by audible neighing, separated by silence. Such vocalisations are 288 
used to regain contact with conspecifics (Houpt, 2001) and may indicate arousal 289 
caused by isolation within the lorry.  290 
 291 
Statistical Analysis 292 
Statistical analysis was carried out using R (R Development Core Team, 2017). The 293 
normality of the sampling distribution was tested using a Shapiro-Wilks test prior to 294 
tests of difference (Field et al., 2012). Paired T-tests or Wilcoxon ranked-sum tests 295 
were used to detect differences between Treatment and Control as appropriate for 296 
normality. Post-hoc effect sizes were calculated (Field et al., 2012; pp 393 & 665) to 297 
determine how meaningful changes in behaviour and physiology were. Power 298 
analysis was conducted on T-tests to determine whether non-significant differences 299 
were due to a lack of effect or insufficient sampling (Field et al., 2012).  300 
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Post-hoc tests of difference were conducted to determine whether an inadequate 301 
wash-out period may have confounded results, limiting the ability to detect a truly 302 
significant effect. If subjects were treated for the first trial, and the supplement had 303 
not completely washed out by the time they were tested for the Control trial, this may 304 
cause an insignificant effect in the whole sample, when in fact, the supplement is 305 
effective. Therefore, for variables that were not significantly affected by treatment in 306 
the whole sample, a subset of subjects who were tested with the control first (n = 5) 307 
were tested for differences between Treatment and Control. Subjects who were 308 
tested with the control first could not have had control trials affected by residual 309 
substance. Therefore, if this test of difference is significant, it indicates that non-310 
significant findings in the whole sample were the result of residual supplementation 311 
and insufficient wash-out period. If the test is insignificant, it confirms non-significant 312 
results seen in the whole cohort. 313 
  314 
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Results 315 
There were no significant differences in physiology between Treatment and Control 316 
(Table 2).  317 
Table 2. Differences in physiological measures between Treatment (T) and Control 318 
(C). Paired T-tests (PT) state the mean, standard deviation (S.D.) and t-value (T) 319 
and statistical power. Wilcoxon Signed-Rank (W) tests state the median, inter-320 
quartile range (IQR) and v-value (V). N = 10 for all tests, except cortisol (N = 9). 321 
Variable Test Mean/ Median S.D./IRQ Test V/ T P 
Effect 
Size 
Power 
Heart Rate 
(bpm) 
T 78.02 21.42 
W 39 0.28 -0.35 NA 
C 75.36 20.43 
Heart Rate 
Variability 
(ms) 
T 73.08 ±32.97 
PT 0.65 0.53 0.21 0.79 
C 66.19 ±32.37 
RMSSD (ms) 
T 47.25 34.62 
W 25 0.77 -0.09 NA 
C 44.65 30.38 
Baseline Core 
Temp. 
(⁰C) 
T 34.66 ±1.17 
PT 0.36 0.73 0.12 0.79 
C 34.37 ±1.64 
Core Temp. Post-
Loading 
(⁰C) 
T 34.86 ±0.64 
PT 0.39 0.7 0.02 0.79 
C 34.65 ±1.48 
Core Temp. Post-
Confinement 
(⁰C) 
T 34.95 ±0.72 
PT 0.8 0.45 0.11 0.82 
C 34.56 ±1.06 
Baseline Temp. 
Discrepancy 
(⁰C) 
T 0.24 ±0.8 
PT -1.32 0.22 0.24 0.92 
C 0.51 ±1.1 
Temp Discrepancy 
Post-Loading 
(⁰C) 
T -0.04 ±0.58 
PT -1 0.34 0.15 0.87 
C 0.19 ±0.55 
Temp. Discrepancy 
Post-Confinement 
(⁰C) 
T 0.3 0.33 
W 30.5 0.76 -0.1 NA 
C 0.1 0.46 
Baseline Cortisol 
(μg/dL) 
T 0.12 ±0.1 
PT -0.84 0.42 0.28 0.71 
C 0.14 ±0.05 
Post-Test Cortisol 
(μg/dL) 
 
T 0.12 ±0.11 
PT -0.14 0.89 0.05 
 
0.89 
 C 0.13 ±0.08 
Change in Cortisol 
(μg/dL) 
T 0.005 ±0.06 
PT 0.93 0.38 0.31 0.86 
C -0.016 ±0.04 
322 
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There was a significant difference in Loading Time, but no other behavioural 323 
indicator differed between Treatment and Control (Table 3).  324 
 325 
Table 3. Differences in behavioural measures between Treatment (T) and Control 326 
(C). Paired T-tests (PT) state the mean, standard deviation (S.D.) and t-value (T) 327 
and statistical power. Wilcoxon Signed-Rank (W) tests state the median, inter-328 
quartile range (IQR) and v-value (V). N = 10 for all tests 329 
Variable Test Mean/Median S.D./IRQ Test V/ T P 
Effect 
Size 
Power 
Loading Time 
(secs) 
T 8.5 1.7 
W 7 0.04 -0.66 NA 
C 8.95 7.83 
Licking & 
Chewing 
T 8.5 8.73 
W 23 0.65 -0.15 NA 
C 11 10.25 
Feet 
Movement 
T 31.5 ±34.56 
PT -0.92 0.38 0.29 0.85 
C 44.5 ±44.67 
Vocalising 
T 2.8 ±2.8 
PT 0.61 0.56 0.2 0.78 
C 2.3 ±2.5 
 330 
 331 
There were no significant differences between Treatment and Control in subjects 332 
tested with Control before Treatment, with the exception of Core Temperature Post-333 
Confinement (Table 4). Power was sufficient in all tests (Tables 2, 3 & 4).  334 
  335 
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Table 4. Differences in measures between horses tested under Control (C) 336 
conditions first and Treatment (T) second (n = 5).  Paired T-tests (PT) state the 337 
mean, standard deviation (S.D.) and t-value (T) and statistical power. Wilcoxon 338 
Signed-Rank (W) tests state the median, inter-quartile range (IQR) and v-value (V).  339 
Variable Test 
Mean/ 
Median 
S.D./IRQ Test V/ T P 
Effect 
Size 
Power 
Heart Rate 
(bpm) 
T 100.59 ±33.3 
PT -1.24 0.28 0.53 0.93 
C 85.06  ±15.59  
Heart Rate Variability 
(ms) 
T 54.97  59.62 
W 7 1 0 NA 
C 52.68 29.19  
RMSSD (ms) 
T 72.34 ±61.31 
PT -0.77 0.48 0.36 0.84 
C 55.5  ±36.31  
Baseline Core Temp. 
(⁰C) 
T 35.0 0.3 
W 2 0.19 -0.59 NA 
C 33.95 0.3 
Core Temp. Post-
Loading 
(⁰C) 
T 34.95 0.85 
W 1 0.13 -0.69 NA 
C 33.75 1.6 
Core Temp. Post-
Confinement 
(⁰C) 
T 35.35 ±0.33 
PT -2.76 0.05 0.81 0.99 
C 34.53 ±0.35 
Baseline Temp. 
Discrepancy 
(⁰C) 
T 0.64 ±0.95 
PT 0.85 0.44 0.31 0.86 
C 0.96 ±1.45 
Temp Discrepancy 
Post-Loading 
(⁰C) 
T -0.1 0.3 
W 3.5 0.58 -0.25 NA 
C -0.1 0.3 
Temp. Discrepancy 
Post-Confinement 
(⁰C) 
T 0.22 ±0.2 
PT -0.99 0.38 0.44 0.89 
C 0.02 ±0.27 
Change in Cortisol 
(μg/dL) 
T 0.04 ±0.05 
PT 2.07 0.13 0.78 0.98 
C -0.02 ±0.07 
Feet Movement 
T 16  2 
W 12 0.31 -0.45 NA 
C 10 14 
Licking & Chewing 
T 17.6 ±10.78 
PT -.057 0.6 0.27 0.80 
C 17.6 ±20.04 
Vocalisation 
T 3 3 
W 3 0.18 -0.6 NA 
C 4 4 
 340 
 341 
 342 
 343 
 344 
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Discussion 345 
Problem behaviour is commonly seen during loading onto vehicles and anticipatory 346 
stress responses are seen in some horses in advance of transport (Schmidt et al., 347 
2010). Supplementation with anti-anxiolytic substances may alleviate stress in this 348 
context and improve both horse welfare and handler safety due to improved 349 
behaviour (McDonnell et al., 2014). The current study aimed to determine the effects 350 
of alpha-casozepine supplementation on the behaviour and physiology of horses 351 
during loading and confinement in a horse lorry. Results indicate limited effects on 352 
behaviour at minimum dosage. 353 
Supplementation with Zylkéne Equine had no significant effects on  the physiological 354 
indicators examined. There was no difference in heart rate, heart rate variability, 355 
RMSSD, core temperature, discrepancy in eye temperature or salivary cortisol 356 
between Treatment and Control. Power analysis for all tests indicate that the sample 357 
size was adequate to detect an effect and therefore these results cannot be 358 
explained by limited sample size. The consistent lack of significant difference across 359 
all variables indicates that, at minimum recommended dosages, Zylkéne Equine was 360 
not effective in reducing anxiety or arousal in the current experiment. It is possible 361 
that the subjects in this experiment were not sufficiently aroused by the tests to 362 
differentiate between treatment and control as they had no known aversion to 363 
loading. On the contrary, if the substance has limited effect, efficacy may be further 364 
reduced in horses with a very pronounced anxiety response.  Therefore, further 365 
testing on horses with known anxiety response to loading is required. 366 
Interestingly, supplementation with Zylkéne Equine did have a significant and 367 
positive effect on time to load. Horses treated with alpha-casozepine loaded 368 
significantly faster into the lorry than when under control conditions. This result 369 
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cannot be explained by the handler biasing the loading procedure as this individual 370 
was blind to the randomised treatment order. Whilst this is a positive indicator that 371 
many horse owners would value, the actual difference in median time was only 0.45 372 
of a second. This is arguably not a meaningful difference that handlers would value. 373 
However, difference in loading time had a statistically strong effect.  Therefore, a 374 
more pronounced differentiation between the two treatments in horses that have 375 
known reluctance to enter a transport vehicle may be possible. However, since the 376 
supplement had no significant effect on physiology, this cannot be assumed. Without 377 
altering the horse’s affective state of arousal or stress, it is not clear how behaviour 378 
would be meaningfully altered. In addition, McDonnell et al., (2014) noted little to no 379 
effect of this supplement on loading time in their study. Within the current sample of 380 
10 horses, it is possible that uncontrollable variations in mood or the environment 381 
account for this difference. No behavioural variable other than time to load was 382 
affected by supplementation. Instances of licking and chewing, vocalising, and 383 
movement within the lorry were not significantly different between treatment and 384 
control. Previous studies noted modest differences in behavioural indicators of stress 385 
and compliance (McDonnell et al., 2014, 2013). However, these studies did not 386 
utilise within individual differences and had small sample sizes, leaving them 387 
vulnerable to the effects of individual differences. 388 
The current study used a paired design which limits the confounding effects of 389 
individual differences on results. One possible limitation of this approach is that 390 
subjects who are tested with the Treatment first may have confounded Control tests 391 
if a complete wash-out is not achieved. However, a sub-sample of subjects that 392 
received Control before Treatment were analysed and most tests of difference were 393 
not significant in this group. The only exception was core temperature post-394 
21 
 
confinement which was significantly different in this sub-group. However, 395 
temperatures were significantly hotter in the treatment group, which does not support 396 
reduced arousal indicative of increased coping in subjects supplemented with 397 
Zylkéne Equine (Valera et al., 2012). Taken as a whole, this suggests that 398 
inadequate wash-out of the supplement does not explain the lack of effect noted in 399 
the current study. 400 
The current study is not without limitations. For ethical considerations, only horses 401 
that were experienced travellers with no known aversion to loading were used and 402 
this may not reflect how the substance would act when used in anxious individuals. 403 
In particular, time taken to load may differ in subjects who find this aversive and 404 
increased arousal may differentiate between treatment and control. Further, the 405 
dosage was the minimum recommended by the manufacturer and manufacturer’s 406 
guidelines are not sensitive to the body weight (Vetoquinol, 2018). Future work 407 
should test the substance at maximum recommended dosages which is 408 
approximately twice what was administered here. In addition, investigating the 409 
effects in subjects with a known aversion to loading is warranted.  410 
 411 
Conclusions 412 
In the current experiment, Zylkéne Equine had no significant effect on heart rate, 413 
heart rate variability, core temperature, discrepancy between eye temperatures or 414 
salivary cortisol. This indicates that this supplement  does not affect a horse’s ability 415 
to cope with loading and confinement in a horse lorry at the dosage used. These 416 
physiological indicators are supported by the behavioural indicators licking and 417 
chewing, feet movement, and vocalising when confined, which also did not differ 418 
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between  treatments. However, horses did load significantly more quickly when 419 
supplemented with alpha-casozepine. Though it is important to note that the median 420 
difference was only 0.45 seconds and is therefore irrelevant.  Further work is 421 
required to ascertain whether the maximum dosage – twice that used here – might 422 
affect coping and behaviour in horses. In addition, it is not clear whether the 423 
difference between Control and Treatment would be differentiated or attenuated by 424 
testing subjects with known anxiety responses during loading.   425 
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